Deutsche Bank began coverage on shares of Teladoc (NYSE:TDOC) in a research report released on Friday, MarketBeat reports. The firm issued a buy rating and a $39.00 target price on the health services provider’s stock.
A number of other brokerages also recently commented on TDOC. Robert W. Baird downgraded shares of Teladoc from an outperform rating to a neutral rating and boosted their target price for the stock from $14.00 to $36.00 in a report on Monday, September 18th. KeyCorp reiterated a buy rating and issued a $37.00 target price on shares of Teladoc in a report on Sunday, September 17th. Zacks Investment Research upgraded shares of Teladoc from a sell rating to a buy rating and set a $38.00 target price for the company in a report on Wednesday, October 4th. Cowen reiterated an outperform rating and issued a $39.00 target price on shares of Teladoc in a report on Saturday, September 30th. Finally, BidaskClub upgraded shares of Teladoc from a sell rating to a hold rating in a report on Wednesday, September 6th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and ten have assigned a buy rating to the stock. The stock presently has a consensus rating of Buy and an average target price of $39.15.
Shares of Teladoc (NYSE TDOC) opened at $32.30 on Friday. The company has a current ratio of 5.08, a quick ratio of 5.08 and a debt-to-equity ratio of 0.83. Teladoc has a fifty-two week low of $15.65 and a fifty-two week high of $37.90.
Teladoc (NYSE:TDOC) last released its quarterly earnings data on Wednesday, November 1st. The health services provider reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.25). The firm had revenue of $68.70 million during the quarter, compared to the consensus estimate of $67.53 million. Teladoc had a negative net margin of 39.61% and a negative return on equity of 21.59%. The business’s revenue was up 112.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.33) earnings per share. equities research analysts anticipate that Teladoc will post -1.57 EPS for the current fiscal year.
In other news, VP Mark Hirschhorn sold 25,000 shares of the business’s stock in a transaction dated Friday, September 22nd. The stock was sold at an average price of $31.93, for a total transaction of $798,250.00. Following the sale, the vice president now owns 64,987 shares in the company, valued at $2,075,034.91. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Jason N. Gorevic sold 20,000 shares of the business’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $33.47, for a total value of $669,400.00. The disclosure for this sale can be found here. Insiders sold 265,000 shares of company stock valued at $8,697,400 over the last quarter. 4.47% of the stock is currently owned by corporate insiders.
Several hedge funds have recently modified their holdings of TDOC. Janus Henderson Group PLC purchased a new stake in shares of Teladoc during the second quarter worth about $58,287,000. Bamco Inc. NY grew its stake in shares of Teladoc by 751.9% during the third quarter. Bamco Inc. NY now owns 1,455,900 shares of the health services provider’s stock worth $48,263,000 after acquiring an additional 1,285,000 shares during the last quarter. BlackRock Inc. grew its stake in shares of Teladoc by 42.9% during the second quarter. BlackRock Inc. now owns 3,844,402 shares of the health services provider’s stock worth $133,400,000 after acquiring an additional 1,154,852 shares during the last quarter. Victory Capital Management Inc. purchased a new stake in shares of Teladoc during the third quarter worth about $35,360,000. Finally, JPMorgan Chase & Co. grew its stake in shares of Teladoc by 65.8% during the second quarter. JPMorgan Chase & Co. now owns 2,663,600 shares of the health services provider’s stock worth $92,426,000 after acquiring an additional 1,057,065 shares during the last quarter.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by Stock Observer and is owned by of Stock Observer. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at https://www.thestockobserver.com/2017/12/12/teladoc-tdoc-research-coverage-started-at-deutsche-bank.html.
Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.
Receive News & Ratings for Teladoc Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Inc and related companies with MarketBeat.com's FREE daily email newsletter.